Status:

COMPLETED

CLOSE-guided Pulmonary Vein Isolation Using High Power and Stable RF Applications

Lead Sponsor:

AZ Sint-Jan AV

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

In this prospective, randomised, controlled, unblinded,monocentric study, we aim to evaluate the safety and efficacy of higher power CLOSE-guided PVI in patients referred for a first ablation for paro...

Detailed Description

BACKGROUND: In a population of paroxysmal AF 'CLOSE'-guided PVI (Target Ablation index (AI) \>550 and \>400 for anterior and posterior wall respectively, interlesion distance ≤6mm) has been shown to o...

Eligibility Criteria

Inclusion

  • All patients referred for symptomatic paroxysmal AF and without advanced structural heart disease
  • Signed Patient Informed Consent Form
  • Age 18 years or older
  • Able and willing to comply with all follow-up testing and requirements

Exclusion

  • Persistent atrial fibrillation (history of AF\>7days or history of cardioversion \> 48h of AF)
  • Previous ablation for AF
  • LA antero-posterior diameter\>50 mm (parasternal long axis view , PLAX)
  • LVEF \<35% (ejection fraction)
  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
  • CABG procedure within the last three months
  • Awaiting cardiac transplantation or other cardiac surgery
  • Documented left atrial thrombus on imaging
  • Diagnosed atrial myxoma
  • Women who are pregnant or breastfeeding
  • Acute illness or active systemic infection or sepsis
  • Unstable angina
  • Uncontrolled heart failure
  • Myocardial infarction within the previous two months
  • History of blood clotting or bleeding abnormalities
  • Contraindication to anticoagulation therapy (ie, heparin or warfarin)
  • Life expectancy less than 12 months
  • Enrollment in any other study evaluating another device or drug
  • Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction

Key Trial Info

Start Date :

February 15 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2020

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04122963

Start Date

February 15 2019

End Date

June 30 2020

Last Update

February 12 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Cardiology

Bruges, Belgium, 8000